Mico BioMed Supplies COVID-19 Diagnostic Equipment and Kits to Colombia

[Asia Economy Reporter Minji Lee] Bio medical diagnostic company Micobiomed announced on the 28th that it will supply COVID-19 diagnostic equipment and kits worth 870 million KRW to Colombia.

This was achieved after being selected as the final supplier for the 'Colombia COVID-19 Comprehensive Emergency Content Program Phase 1 Supply' project led by the Korea International Cooperation Agency (KOICA). The equipment to be supplied includes three on-site diagnostic real-time gene amplification devices, one nucleic acid extraction device, and extraction kits for 200,000 tests. The total supply, worth 870 million KRW, is scheduled to be completed within this year.

The equipment applies Micobiomed's core technology, 'Lab-on-a-Chip,' demonstrating excellence in various areas such as speed, accuracy, and cost-effectiveness. Since this emergency support project for Colombia is a government-led initiative targeting developing countries, it can also be interpreted as proof of Micobiomed's technology optimized for point-of-care testing (POCT).

A Micobiomed official stated, "Through this project, we expect the excellent capabilities of K-diagnostics to spread to developing countries, resulting in practical effects such as reduced diagnostic time and protection of medical personnel," adding, "We will continue post-management to enhance infectious disease prevention capabilities beyond simple quarantine material support."

Meanwhile, Micobiomed is preparing for a listing on the KOSDAQ market at the end of October. Although it submitted a securities registration statement in August and entered the public offering process, the listing schedule was delayed by one month due to minor supplementary matters regarding the registration statement.